Sofinnova'speople
Individual strengths, united purpose
We embrace individual uniqueness and diversity, while our greatest strength is in our unity and common purpose.
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Henrijette Richter
Managing Partner, Sofinnova Partners
Monique Saulnier
Managing Partner, Sofinnova Partners
Graziano Seghezzi
Managing Partner, Sofinnova Partners
Joe Anderson
Partner, Sofinnova Partners Crossover Strategy
Guillaume Baxter
Principal, Sofinnova Partners Industrial Biotech Strategy
Anna Belousova
Analyst, Sofinnova Partners Industrial Biotech Strategy
Maina Bhaman
Partner, Sofinnova Partners Capital Strategy
Joško Bobanović
Partner, Sofinnova Partners Industrial Biotech Strategy
Tom Burt
Partner, Sofinnova Partners Crossover Strategy
Claire Catherinet
Associate, Sofinnova Partners Crossover Strategy
Anouck Champsaur
Associate, Sofinnova Partners Industrial Biotech Strategy
Cécile Dupont
Principal, Program Director, Sofinnova Partners MD Start Strategy
Marie Duranteau
Senior Analyst, Sofinnova Partners Capital Strategy
Lucia Faccio
Partner, Sofinnova Partners Telethon Strategy
Marion Gasperment
Associate, Program Manager, Sofinnova Partners MD Start Strategy
Anta Gkelou
Principal, Sofinnova Partners Capital Strategy
Lukas Guenther
Partner, Sofinnova Partners MD Start Strategy
Kuang He
Associate, Sofinnova Partners Crossover Strategy
Kinam Hong
Partner, Sofinnova Partners Crossover Strategy
Ankeet Jethwa
Associate, Sofinnova Partners Capital Strategy
Edward Kliphuis
Partner, Sofinnova Partners
Michael Krel
Partner, Sofinnova Partners Industrial Biotech Strategy
Denis Lucquin
Partner Emeritus, Sofinnova Partners Industrial Biotech Strategy
Cedric Moreau
Partner, Sofinnova Partners Crossover Strategy
Javier Nunez-Vicandi
Senior Associate, Sofinnova Partners
Anne Osdoit
Partner, Sofinnova Partners MD Start Strategy
Paola Pozzi
Partner, Sofinnova Partners Telethon Strategy
Tiziana Rossetti
Senior Associate, Sofinnova Partners Telethon Strategy
Jacques Theurillat
Partner, Sofinnova Partners Crossover Strategy
Simon Turner
Partner, Sofinnova Partners
ZhiZhong (Joel) Yao
Principal, Sofinnova Partners Capital Strategy
Malty Ba
Reporting Officer, Sofinnova Partners
Thomas Bermudes
Senior Legal Counsel, Sofinnova Partners
Christophe Blanche
Chief Financial Officer, Sofinnova Partners
Armance Bordes
General Counsel, Sofinnova Partners
Robert Carroll
Partner, Head of Investor Relations, ESG and Impact, Sofinnova Partners
Gabriel Challot
Communications Designer, Sofinnova Partners
Laura Daudin-Antoine
Legal Counsel, Sofinnova Partners
Bertrand Echalard
Management Company Accounting, Sofinnova Partners
Mats Eklund
Partner and Chief Operating Officer, Sofinnova Partners
Juliette Grant
Executive Assistant, Sofinnova Partners
Johanna Guacide
Funds Accounting, Sofinnova Partners
Stéphanie Huiban
Head of Information Systems, Sofinnova Partners
Sarah Lafaye
Investor Reporting, Sofinnova Partners
Marc Lahoudie
IT Support, Sofinnova Partners
Sandrine Le Penru
Executive Assistant, Sofinnova Partners
Aziliz Le Roux
Investor Relations, Sofinnova Partners
Bommy Lee
Head of Communications, Sofinnova Partners
Delphine Linard
Executive Assistant, Sofinnova Partners
Nathalie Loreaux
Investor Relations and Reporting Manager, Sofinnova Partners
Caroline Patard
Administrative and Financial Manager, Sofinnova Partners
Paola Pizzi
Head of Operations, Italy, Sofinnova Partners
Ashvin Rajee
Paralegal, Sofinnova Partners
Estelle Rigaux
Compliance Officer, Sofinnova Partners
Dominique Verdier
Reception and Administration, Sofinnova Partners
Lamia Verney
Executive Assistant, Sofinnova Partners
Gabriella Camboni
Venture Partner
Gérard Hascoët
Venture Partner, Sofinnova Partners
Mano Iyer
Venture Partner, Sofinnova Partners
Silvano Spinelli
Venture Partner, Sofinnova Partners
Martin T. Rothman
Venture Partner, Sofinnova Partners
Articles about the team
Calliditas announces primary endpoint successfully met in Phase 3 NefIgArd trial evaluating Nefecon® in IgA nephropathy
Enthera Pharmaceuticals initiates Phase 1 clinical trial with lead candidate Ent001
Noema Pharma, founded by Sofinnova Partners, raises CHF 103 million (USD112million) in Series B financing
Elicit Plant appoints Pam Marrone and Johan de Saegher to its Board of Directors
Chroma Medicine secures $135M in Series B financing to advance breakthrough epigenetic editing technology and expand pipeline of durable precision genomic medicines